Get the Daily Brief
Latest Biotech News
Novo Nordisk Foundation commits up to $850M: BioInnovation Institute to scale across Europe
The Novo Nordisk Foundation pledged up to $850 million to expand the BioInnovation Institute (BII) beyond Denmark and accelerate European life‑science startups. BII, spun out of the foundation,...
DNA fragments dodge screening: researchers show synthesis checks can be bypassed
A team led by Edison, Toner and Esvelt published a study demonstrating that assembling unregulated DNA fragments can circumvent current commercial DNA synthesis screening pipelines. The work,...
GT Biopharma files IND for TriKE — Medicenna advances MDNA‑113 toward IND
GT Biopharma filed an IND for GTB‑5550, a B7‑H3‑targeted TriKE intended for B7‑H3‑expressing solid tumors; the company plans a Phase 1 basket trial with subcutaneous dosing pending FDA clearance....
U.K. launches Synthetic Human Genome moonshot: £10M SynHG to build genome‑writing tools
A Wellcome‑funded five‑year Synthetic Human Genome (SynHG) consortium received £10 million to develop foundational technologies for large‑scale chromosome engineering, aiming to create reliable...
Off-the-shelf CAR‑NK: Durable complete responses in Waldenström’s
Early clinical data show ImmunityBio’s off-the-shelf CD19 CAR‑NK therapy produced durable complete responses in heavily pretreated Waldenström’s macroglobulinemia patients. Company reports — drawn...
ARPA‑H funds UC San Diego to 3D‑print patient livers
ARPA‑H awarded UC San Diego a $25.77 million, 60‑month grant to develop patient‑specific, 3D‑bioprinted human livers under the PRINT program. The multidisciplinary team will combine rapid...
Epkinly misses endpoint: No overall survival benefit in DLBCL study
AbbVie and Genmab reported that Epkinly failed to extend overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL) patients who had received at least one prior therapy. The...
Vedanta refocuses on VE303 — deep cuts to preserve Phase 3 runway
Vedanta Biosciences sharply reduced headcount and furloughed staff to concentrate remaining resources on its lead live‑biotherapeutic candidate VE303 and its Phase 3 program for recurrent...
Labcorp expands MRD and NGS offerings; Watchmaker, Saga add tools
Labcorp launched two new circulating tumor DNA assays — Plasma Detect ID (personalized whole‑exome guided panels) and Plasma Detect Genome (whole‑genome MRD) — to broaden its MRD portfolio across...
Novo Nordisk Foundation pledges up to $850M to scale European biotech
The Novo Nordisk Foundation committed up to $850 million to expand the BioInnovation Institute beyond Denmark to a pan‑European reach. The funding will support early‑stage startups, scaling of...
SpyGlass, Agomab file IPOs after JPM — investor momentum continues
SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings following investor interest sparked at J.P. Morgan Healthcare Conference. Both drug developers aim to leverage the window...
EU grant backs Destina’s LiverAce assay for drug‑induced liver injury
Destina Genomica secured €2.2 million via an EIC funding stream to advance LiverAce Combo, a PCR‑free assay that measures RNA (miR‑122) and protein (CK‑18) biomarkers simultaneously for early...
JPM week funding surge: cash inflows and headline stock moves
Industry finance reports show increased capital flows into biotech during the J.P. Morgan Healthcare Conference, with new funds announced and deal activity accelerating. BioCentury flagged...
Gene‑drive moves into field‑relevant testing in Africa
Researchers adapted a previously developed gene‑drive strategy to a local Tanzanian mosquito strain and tested an antiparasitic transgene (MM‑CP) expressing magainin‑2 and melittin in a secure...
ImmunityBio CAR‑NK posts durable complete responses – outpatient regimen
ImmunityBio disclosed durable complete responses in a small cohort of Waldenström’s macroglobulinemia patients treated with its off‑the‑shelf CD19 CAR‑NK therapy alongside rituximab. The company...
Tecvayli shows survival benefit — Johnson & Johnson presses advantage
Johnson & Johnson reported Phase 3 data showing Tecvayli reduced the risk of disease progression or death versus standard regimens in relapsed multiple myeloma. Trial monitors detected an early...
Epkinly fails to extend overall survival in late‑stage lymphoma
AbbVie and Genmab announced that Epkinly did not prolong overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The negative top‑line outcome applies to patients who had...
UC San Diego wins ARPA‑H grant to 3D‑print patient livers — $25.8M award
UC San Diego secured up to $25.77 million from ARPA‑H to develop patient‑specific 3D‑bioprinted livers over a 60‑month program. The multidisciplinary project aims to fabricate fully functional,...
Vedanta cuts workforce to focus on VE303 Phase 3 push
Vedanta Biosciences confirmed a significant reduction in headcount as it reallocates remaining resources to advance VE303, its lead live bacterial consortium for prevention of recurrent...
Conference week fuels capital flows — financings and Q4 pickup
Industry trackers reported a marked increase in cash flowing into biotech during JP Morgan week and a late‑year surge in financings. BioCentury noted heightened deal and fund activity tied to...